<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848181</url>
  </required_header>
  <id_info>
    <org_study_id>benign prostatic hyperplasia</org_study_id>
    <nct_id>NCT04848181</nct_id>
  </id_info>
  <brief_title>The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate</brief_title>
  <official_title>The Effect of Short Term Use of Finasteride Versus Cyproterone Acetate on Perioperative Blood Loss With Mono Polar Transurethral Resection of Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative bleeding is the most common complication related to transurethral resection of&#xD;
      prostate, the aim of the study is to compare the effect of pre-operative use of finasteride&#xD;
      versus Cyproterone acetate on blood loss with mono polar TURP&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized controlled study to compare the effect of pre-operative use of&#xD;
      finasteride versus Cyproterone acetate on blood loss with mono polar TURP&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">July 9, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post operative Hb</measure>
    <time_frame>24 hour post operative</time_frame>
    <description>measuring serum haemoglobin level at first post operative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post operative Hcv</measure>
    <time_frame>24 hour post operative</time_frame>
    <description>measuring serum haematocrit value at first post operative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>operative duration</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>assessment of the duration of the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>microvascular density(MVD)</measure>
    <time_frame>2 weeks after drug intake</time_frame>
    <description>assesment of MVD of the prostate by histological examination using high power field microscope</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>assessment of intraoperative blood loss during TURP</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>cyproterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients received cyproterone acetate 50 mg twice per day for two weeks before TURP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>finasteride group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients received finasteride 5 mg once per day for two weeks before TURP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients received no treatment before TURP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproterone acetate</intervention_name>
    <description>two weeks Cyproterone acetate administration before TURP</description>
    <arm_group_label>cyproterone acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>finasteride</intervention_name>
    <description>two weeks finasteride administration before TURP</description>
    <arm_group_label>finasteride group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>no treatment received</intervention_name>
    <description>no treatment received before TURP</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with benign prostatic hyperplasia with prostate size (60-100) grams&#xD;
&#xD;
          -  Lower urinary tract symptoms (LUTS) not responding to medical treatment&#xD;
&#xD;
          -  Recurrent prostatic bleeding&#xD;
&#xD;
          -  Recurrent acute urinary retention&#xD;
&#xD;
          -  Chronic urinary retention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with coagulation disorders&#xD;
&#xD;
          -  Previous prostatic surgery&#xD;
&#xD;
          -  Previous finasteride administration&#xD;
&#xD;
          -  Bladder pathology (urinary bladder stones - bladder mass)&#xD;
&#xD;
          -  Suspected or proved cancer prostate&#xD;
&#xD;
          -  Hepatic or renal impairment&#xD;
&#xD;
          -  Patients unfit for operation eg. Decompensated heart failure, poor chest condition&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shabieb ahmed, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>faculty of medicine benha university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>abdallah fathy, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>faculty of medicine benha university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohamed hefnawy, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>faculty of medicine benha university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>adel al falah, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of medicine benha university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benha University</name>
      <address>
        <city>Banhā</city>
        <state>Qalyubia</state>
        <zip>15311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Treharne C, Crowe L, Booth D, Ihara Z. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. Eur Urol Focus. 2018 Mar;4(2):270-279. doi: 10.1016/j.euf.2016.03.002. Epub 2016 Mar 23.</citation>
    <PMID>28753756</PMID>
  </reference>
  <reference>
    <citation>Yang TY, Chen M, Lin WR, Li CY, Tsai WK, Chiu AW, Ko MC. Preoperative treatment with 5α-reductase inhibitors and the risk of hemorrhagic events in patients undergoing transurethral resection of the prostate - A population-based cohort study. Clinics (Sao Paulo). 2018 Mar 12;73:e264. doi: 10.6061/clinics/2018/e264.</citation>
    <PMID>29538495</PMID>
  </reference>
  <reference>
    <citation>Khwaja MA, Nawaz G, Muhammad S, Jamil MI, Faisal M, Akhter S. The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity. J Coll Physicians Surg Pak. 2016 Mar;26(3):213-5. doi: 03.2016/JCPSP.213215.</citation>
    <PMID>26975954</PMID>
  </reference>
  <reference>
    <citation>Tian HL, Zhao CX, Wu HY, Xu ZX, Wei LS, Zhao RT, Jin DL. Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats. Am J Med Sci. 2015 Jun;349(6):516-20. doi: 10.1097/MAJ.0000000000000451.</citation>
    <PMID>25789687</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Shabieb Ahmed</investigator_full_name>
    <investigator_title>shabieb ahmed ( assistant professor - urology department - Benha University)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

